CPT2 | Carnitine palmitoyltransferase 2 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
CRBN | Cereblon | Disease related genes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
CYP11B1 | Cytochrome P450, family 11, subfamily B, polypeptide 1 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted intracellular proteins
| | | | | Tissue enriched |
CYP17A1 | Cytochrome P450, family 17, subfamily A, polypeptide 1 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
CYP19A1 | Cytochrome P450, family 19, subfamily A, polypeptide 1 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
CYP51A1 | Cytochrome P450, family 51, subfamily A, polypeptide 1 | Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CYSLTR1 | Cysteinyl leukotriene receptor 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Mixed |
CYSLTR2 | Cysteinyl leukotriene receptor 2 | FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
DBH | Dopamine beta-hydroxylase (dopamine beta-monooxygenase) | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enriched |
DCK | Deoxycytidine kinase | Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
DDC | Dopa decarboxylase (aromatic L-amino acid decarboxylase) | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
DHFR | Dihydrofolate reductase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Mixed |
DHODH | Dihydroorotate dehydrogenase (quinone) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
DNMT1 | DNA (cytosine-5-)-methyltransferase 1 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
DPEP1 | Dipeptidase 1 (renal) | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
DPP4 | Dipeptidyl-peptidase 4 | CD markers Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
DRD1 | Dopamine receptor D1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
DRD2 | Dopamine receptor D2 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
DRD5 | Dopamine receptor D5 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
EDNRA | Endothelin receptor type A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
EDNRB | Endothelin receptor type B | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
EGF | Epidermal growth factor | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| | | | | Group enriched |
EGFR | Epidermal growth factor receptor | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
EPHA2 | EPH receptor A2 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins RAS pathway related proteins
| | | | | Tissue enhanced |
ERBB2 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
ERBB4 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
ESR1 | Estrogen receptor 1 | Cancer-related genes Disease related genes FDA approved drug targets Nuclear receptors Predicted intracellular proteins Transcription factors
| | | | | Group enriched |
ESR2 | Estrogen receptor 2 (ER beta) | Cancer-related genes FDA approved drug targets Nuclear receptors Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
ESRRG | Estrogen-related receptor gamma | FDA approved drug targets Nuclear receptors Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
F2 | Coagulation factor II (thrombin) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enriched |
FADS1 | Fatty acid desaturase 1 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
FADS2 | Fatty acid desaturase 2 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
FASN | Fatty acid synthase | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
FCER1A | Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide | FDA approved drug targets Predicted membrane proteins
| | | | | Mixed |
FCER1G | Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide | FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |
FDPS | Farnesyl diphosphate synthase | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
FGF1 | Fibroblast growth factor 1 (acidic) | Cancer-related genes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Group enriched |
FGF2 | Fibroblast growth factor 2 (basic) | Cancer-related genes Candidate cardiovascular disease genes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Mixed |
FGFR1 | Fibroblast growth factor receptor 1 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Expressed in all |
FGFR2 | Fibroblast growth factor receptor 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
FKBP1A | FK506 binding protein 1A, 12kDa | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
FLT1 | Fms-related tyrosine kinase 1 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enriched |
FLT3 | Fms-related tyrosine kinase 3 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
FLT4 | Fms-related tyrosine kinase 4 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
FRK | Fyn-related Src family tyrosine kinase | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Mixed |
FTH1 | Ferritin, heavy polypeptide 1 | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
FTL | Ferritin, light polypeptide | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
FXYD2 | FXYD domain containing ion transport regulator 2 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
GAA | Glucosidase, alpha; acid | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
GABBR1 | Gamma-aminobutyric acid (GABA) B receptor, 1 | FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |